Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts
Open Access
- 25 February 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 31 (6), 973-981
- https://doi.org/10.1007/s10067-012-1962-z
Abstract
Systemic sclerosis (SSc) is a chronic fibrosing disease characterized by vasculopathy, autoimmunity, and an accumulation of collagen in tissues. Numerous studies have shown that compared to healthy or diseased controls, the peripheral blood mononuclear cells (PBMC) from patients with SSc produce a variety of cytokines or proliferate when cultured with solubilized type I collagen (CI) or constituent α1(II) and α2(I) polypeptide chains. The purpose of this study was to determine whether PBMC isolated from patients with SSc and cultured in vitro with soluble CI elaborated soluble mediators that inhibit the production of collagenase (i.e., matrix metalloproteinase, MMP-1) by fibroblasts. Supernatants of CI-stimulated PBMC from juvenile and adult diffuse cutaneous (dc)SSc patients significantly reduced MMP-1 production by SSc dermal fibroblasts, while supernatants of CI-stimulated PBMC from patients with localized scleroderma (LS) did not. CI-stimulated PBMC culture supernatants from patients with dcSSc in contrast to patients with LS exhibited increased levels of platelet-derived growth factor (PDGF)-AA, PDGF-BB, TNF-α, IL-13, and EGF. Prolonged culture of SSc dermal fibroblasts with recombinant PDGF-BB or IL-13 inhibited the induction of MMP-1 in response to subsequent TNF-α stimulation. These data suggest that therapies aimed at reducing these cytokines may decrease collagen accumulation in SSc, preventing the development of chronic fibrosis.This publication has 38 references indexed in Scilit:
- Update on morphea: Part I. Epidemiology, clinical presentation, and pathogenesisJournal of the American Academy of Dermatology, 2011
- Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma)Clinical and Experimental Immunology, 2010
- Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestationsArthritis Research & Therapy, 2009
- EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cellsAnnals Of The Rheumatic Diseases, 2008
- Epidermal growth factor up‐regulates expression of transforming growth factor β receptor type II in human dermal fibroblasts by phosphoinositide 3‐kinase/Akt signaling pathway: Resistance to epidermal growth factor stimulation in scleroderma fibroblastsArthritis & Rheumatism, 2003
- Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalitiesClinical Rheumatology, 2003
- Transforming Growth Factor-β Repression of Matrix Metalloproteinase-1 in Dermal Fibroblasts Involves Smad3Online Journal of Public Health Informatics, 2001
- Cytokine production and serum levels in systemic sclerosisClinical Immunology and Immunopathology, 1992
- Immune Response to Connective Tissue Components of the Basement MembraneConnective Tissue Research, 1982
- Zelluläre Immunphänomene bei der SklerodermieDermatology, 1977